PHASE-II EVALUATION OF VINDESINE IN PATIENTS WITH NON-SMALL CELL-CARCINOMA OF THE LUNG

  • 1 January 1979
    • journal article
    • research article
    • Vol. 63  (8) , 1343-1346
Abstract
Patients (52) with non-small cell carcinoma of the lung were treated i.v. with doses of vindesine at 3-4 mg/m2 per week i.v. Partial responses occurred in all histologic types in 10 of 46 adequately treated patients, for an overall response rate of 22%. Patients not previously treated with chemotherapy had a higher response rate than those who had received prior chemotherapy (33% vs. 12%). Reversible peripheral neuropathy occurred in all patients, and was generally of a mild to moderate degree. Mild leukopenia was seen frequently, with a median wbc (white blood cells) nadir of 2900/mm3. As reported with the older Vinca alkaloids, platelet-sparing with occasional episodes of thrombocytosis occurred with vindesine. Vindesine is an active agent in non-small cell carcinoma of the lung and that further studies in previously untreated patients are indicated.